Host metadherin coordinates hepatic lipid metabolism and CD8(+) T cell immunity to promote tumor progression.

Loss of host metadherin (MTDH) in mice enhances CD8(+) T cell activity and reduces tumor growth by restoring liver lipid metabolism, with a 50% decrease in metastasis.

• Why it matters: Understanding how primary tumors influence distant organ functions and immune responses is crucial for developing effective cancer therapies, especially for metastatic disease.
• What they did: Researchers used Mtdh knockout mice to investigate tumor-liver interactions, analyzing immune cell function, lipid metabolism, and tumor progression, and combined genetic and pharmacological approaches.
• The result: Targeting MTDH improved antitumor immunity and synergized with anti-PD-1 therapy, highlighting MTDH as a promising therapeutic target to disrupt tumor-induced immunosuppression and systemic cancer progression.